ESMO 2023丨中国肝癌研究一览

946P - Sintilimab plus Lenvatinib as Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study

947P - The Efficacy and Safety of Cadonilimab Combined with Lenvatinib for First-line Treatment of Advanced Hepatocellular Carcinoma: A Phase Ib/II Clinical Trial

948P - Phase (Ph) 1/2 Study of Sitravatinib (Sitra) Alone or With Tislelizumab (TIS) in Advanced Hepatocellular Carcinoma (HCC) and Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

949P - Regorafenib combined with immunotherapy versus regorafenib as second-line therapy in patients with advanced hepatocellular carcinoma: A multicenter real-world study

950P - Phase II clinical study of sorafenib combined with tislelizumab in the treatment of first-line unresectable hepatocellular carcinoma and the predictive effect and correlation of CTC

951P - HAIC combined with anlotinib and TQB2450 as adjuvant therapy for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after hepatectomy: a single-centre, non-randomised, open clinical study

952P - Efficacy and safety of a PRospective, Observational trial of Lenvatinib cOmbined with transarterial chemoembolization (TACE) as initial treatment for advaNced staGe hepatocellular carcinoma (PROLONG): a multicenter, single-armed, real-world study

953P - Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): a single-arm, phase 2 trial

954P - Radiotherapy combined with tislelizumab plus anlotinib as first-line treatment for hepatocellular carcinoma: a single arm, phase Ⅱ clinical trial

956P - Phase 2 study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion

957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable HCC

958P - Preliminary results of radiotherapy (RT) combined with sintilimab (Sin) and bevacizumab (Bev) in advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICIs): A prospective phase II study

959P - Combination Therapy of Envafolimab and Suvemcitug in Patients with Hepatocellular Carcinoma (HCC): Results from a Phase II Clinical Trial

962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation

963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)

965P - C14orf159 mutations are associated with shorter relapse-free survival and overall survival after liver transplantation in hepatocellular carcinoma patients meeting Hangzhou criteria

968P - High Sensitivity Routine Blood Based Detection of HCC: An AI Model from 220k Patients

969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data

971P - Effect of Preoperative Frailty on Surgical Outcomes Following Hepatic Resection for Elderly Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study from China

974P - The Barthel Index Predicts Surgical Textbook Outcomes Following Hepatectomy for Elderly Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study from China

977P - Hepatic arterial infusion chemotherapy (HAIC) combined with Regorafenib and PD-1 inhibitors versus Regorafenib combined with PD-1 inhibitors for second-line treatment Hepatocellular carcinoma (HCC)

982P - Transarterial Chemoembolization with Idarubicin versus Epirubicin for Hepatocellular Carcinoma: an Interim Analysis of a Multicentre, Randomized Controlled phase 3 trial

983P - Safety and Efficacy of Durvalumab plus Hepatic Artery Infusion Chemotherapy in HCC with Severe Portal Vein Tumor Thrombosis (Vp3/4) – the DurHope Study

990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model

992P - Analyzing effectiveness and safety of standard-dose and low-dose bevacizumab combination with atezolizumab in patients with unresectable hepatocellular carcinoma: a multi-institutional study in Taiwan

996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study

997P - A practical risk classification of early recurrence and long term survival outcomes in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy: a decision tree analysis

998P - Efficacy and Safety of Curative Hepatectomy after Conversion Therapies for Initial Unresectable Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Study

999P - Donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II trial (DoHAICs study)

1002P - Efficacy and safety of tislelizumab combined with TKIs and FOLFOX4-HAIC in conversion therapy of unresectable hepatocellular carcinoma

1004P - Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: a retrospective, multi-center, real-world study

1005P - Atezolizumab plus bevacizumab combined with transarterial chemoembolization and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma with high tumor burden

1008P - The safety and efficacy of PD-1 inhibitor (Sintilimab) combined with conventional transarterial chemoembolization (cTACE) for the initial treatment of the stage BCLC B hepatocellular carcinoma (HCC) beyond up-to-seven criteria

1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus

1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression

1013TiP - Refinement and Validation of a Comprehensive Clinical Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma: A Multicenter, Prospective Study Protocol

1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study

1015TiP - A Prospective, Phase II Clinical Study of Tislelizumab monotherapy or in Combination with Lenvatinib for neoadjuvant Treatment of Resectable Hepatocellular Carcinoma

91P - Erythroid Precursor-Differentiated Myeloid Cells promote Pulmonary metastasis in Hepatocellular Carcinoma

945MO - AdvanTIG-206: Phase 2 Randomized Open-Label Study of Ociperlimab (OCI) + Tislelizumab (TIS) + BAT1706 (Bevacizumab Biosimilar) Versus TIS + BAT1706 in Patients (pts) With Advanced Hepatocellular Carcinoma (HCC)

讲者：Ming Mo Hou（中国台湾）